Clinical Research Directory
Browse clinical research sites, groups, and studies.
Nebulized Ketamine for the Treatment of Major Depressive Disorder
Sponsor: Theresa Jacob, PhD, MPH
Summary
This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.
Official title: Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting: A Midazolam-controlled Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 88 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-10-16
Completion Date
2027-09-30
Last Updated
2026-04-24
Healthy Volunteers
No
Conditions
Interventions
nebulized ketamine
The formulation of the study drug is administered via nebulizer in which the participants inhales the study drug. The dosage is calculated by body weight (1.5mg/kg).
nebulized midazolam
The formulation of the active comparator drug is administered via nebulizer in which the participant inhales the study drug. The dosage is calculated by body weight (0.03mg/kg).
Locations (1)
Maimonides Medical Center
Brooklyn, New York, United States